Valuation Metrics Reflect a Positive Recalibration
At the heart of National Peroxide’s renewed appeal lies a marked improvement in key valuation parameters. The company’s price-to-earnings (P/E) ratio currently stands at 27.08, a figure that, while not low in absolute terms, is notably attractive when compared to its peer group. For context, competitors such as Titan Biotech and Stallion India trade at P/E ratios of 75.5 and 40.02 respectively, both classified as very expensive. This relative moderation in P/E suggests that National Peroxide’s shares are priced more reasonably in relation to earnings potential.
Equally telling is the price-to-book value (P/BV) ratio of 0.90, which indicates the stock is trading below its book value. This is a significant shift from prior perceptions of risk and suggests the market may be undervaluing the company’s net asset base. The enterprise value to EBITDA (EV/EBITDA) ratio of 8.56 further supports this view, positioning National Peroxide comfortably within the ‘very attractive’ valuation category. By contrast, peers such as Sanstar and Titan Biotech exhibit EV/EBITDA multiples exceeding 60, underscoring the relative affordability of National Peroxide’s shares.
Market Performance and Capitalisation Context
National Peroxide’s market capitalisation remains in the micro-cap segment, which often entails higher volatility but also greater potential for price appreciation. The stock’s recent trading activity has been robust, with a day change of 20.00% and a current price of ₹547.60, up from the previous close of ₹456.35. This surge reflects growing investor confidence following the valuation upgrade and the company’s improving fundamentals.
Over the short term, the stock has outperformed the benchmark Sensex index significantly. For instance, in the past week, National Peroxide delivered a return of 29.9%, while the Sensex was essentially flat at -0.04%. Over the last month, the stock’s return of 44.11% dwarfs the Sensex’s 5.39% gain. Even year-to-date, the company has posted a positive 17.01% return compared to the Sensex’s decline of 9.33%. These figures highlight the stock’s strong momentum and resilience amid broader market fluctuations.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Comparative Valuation: National Peroxide vs Peers
When analysing National Peroxide’s valuation in the context of its industry peers, the company emerges as a standout candidate for value investors. While several peers are classified as very expensive, National Peroxide’s valuation grade has improved dramatically from ‘risky’ to ‘very attractive’. This is underscored by its PEG ratio of 0.04, which is exceptionally low and suggests that the stock’s price growth is not outpacing earnings growth, a positive sign for sustainable valuation.
Other companies in the commodity chemicals sector, such as Gulshan Polyols and TGV Sraac, also enjoy ‘very attractive’ valuations but differ in their multiples. For example, Gulshan Polyols trades at a P/E of 27.24 and an EV/EBITDA of 11.91, slightly higher than National Peroxide’s metrics, indicating that National Peroxide may offer a more compelling entry point.
Financial Performance and Quality Metrics
Despite the positive valuation shift, some financial metrics warrant cautious consideration. National Peroxide’s latest return on capital employed (ROCE) is negative at -3.43%, signalling challenges in generating returns from its capital base. However, the return on equity (ROE) remains positive at 3.32%, indicating modest profitability for shareholders. These figures suggest that while the company is improving its market valuation, operational efficiency and profitability still require enhancement to fully justify the current price levels.
The absence of a dividend yield further emphasises the company’s focus on reinvestment or growth rather than shareholder payouts at this stage. Investors should weigh these factors alongside valuation improvements when considering the stock’s risk-reward profile.
Price Range and Volatility Considerations
National Peroxide’s 52-week price range spans from ₹350.00 to ₹770.00, with the current price of ₹547.60 positioned closer to the upper end of this spectrum. This suggests that the stock has recovered significantly from its lows, reflecting renewed investor interest and confidence. The intraday trading range on the latest session was tight, with both the high and low at ₹547.60, indicating strong buying interest at this level.
Given the micro-cap status and recent price volatility, investors should be prepared for potential fluctuations but can also benefit from the stock’s demonstrated capacity for sharp upward moves.
Thinking about National Peroxide Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Outlook and Investment Implications
National Peroxide’s upgrade in valuation attractiveness and Mojo Grade from Sell to Buy as of 4 May 2026 reflects a significant shift in market sentiment. With a Mojo Score of 72.0, the company is now favourably rated within the commodity chemicals sector. Investors looking for exposure to micro-cap stocks with improving fundamentals and reasonable valuations may find National Peroxide an appealing candidate.
However, the company’s negative ROCE and modest ROE highlight the need for ongoing operational improvements. The valuation metrics suggest that the market is pricing in a turnaround or growth potential, but realisation of this potential will be critical to sustain the current price levels.
Comparatively, National Peroxide offers a more attractive entry point than many of its peers, which trade at significantly higher multiples. This relative value, combined with strong recent price performance and positive momentum, supports a cautiously optimistic investment stance.
Investors should continue to monitor quarterly earnings, capital efficiency metrics, and sector dynamics to assess whether the valuation premium is justified over time.
Summary
In summary, National Peroxide Ltd’s valuation parameters have undergone a meaningful improvement, shifting from risky to very attractive territory. The company’s P/E ratio of 27.08 and P/BV of 0.90 stand out favourably against peers, while its EV/EBITDA multiple of 8.56 further confirms its relative affordability. Despite some operational challenges reflected in ROCE and ROE figures, the stock’s strong recent price performance and upgraded Mojo Grade signal renewed investor confidence. For those seeking exposure to the commodity chemicals sector with a focus on value and growth potential, National Peroxide merits close attention.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
